Reply to the letter to the editor 'The ESMO Magnitude of Clinical Benefit Scaling Tool: from theory to practice' by Hartmann and the letter 'Comment on ESMO Magnitude of Clinical Benefit Scale' by Muhonen et al.
作者信息
Cherny N I, Sullivan R, Dafni U, Kerst J M, Sobrero A, Zielinski C, de Vries E G E, Piccart M J
机构信息
Department of Medical Oncology, Cancer Pain and Palliative Medicine Service, Shaare Zedek Medical Center, Jerusalem, Israel
Kings Health Partners Integrated Cancer Centre, King's College London, Institute of Cancer Policy, London, UK.
出版信息
Ann Oncol. 2016 Jan;27(1):203-5. doi: 10.1093/annonc/mdv502. Epub 2015 Oct 30.
PMID:26519490
Abstract
摘要
相似文献
1
Reply to the letter to the editor 'The ESMO Magnitude of Clinical Benefit Scaling Tool: from theory to practice' by Hartmann and the letter 'Comment on ESMO Magnitude of Clinical Benefit Scale' by Muhonen et al.对哈特曼所著致编辑的信《欧洲肿瘤内科学会临床获益程度量表：从理论到实践》以及穆霍宁等人所著信《关于欧洲肿瘤内科学会临床获益程度量表的评论》的回复
Ann Oncol. 2016 Jan;27(1):203-5. doi: 10.1093/annonc/mdv502. Epub 2015 Oct 30.
2
Reply to the letter to the editor 'The ESMO Magnitude of Clinical Benefit Scaling Tool: from theory to practice' by Hartmann and the letter 'Comment on ESMO Magnitude of Clinical Benefit Scale' by Muhonen et al.
Ann Oncol. 2016 Jan;27(1):205-207. doi: 10.1093/annonc/mdv502. Epub 2019 Dec 4.
3
The ESMO magnitude of clinical benefit scaling tool: from theory to practice.
Ann Oncol. 2015 Nov;26(11):2357-8. doi: 10.1093/annonc/mdv367. Epub 2015 Sep 7.
4
A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS).一种标准化、通用且经过验证的方法，用于对预期从抗癌治疗中获得的临床获益程度进行分层：欧洲肿瘤内科学会临床获益程度量表（ESMO-MCBS）。
Ann Oncol. 2015 Aug;26(8):1547-73. doi: 10.1093/annonc/mdv249. Epub 2015 May 30.
5
Five years of EMA-approved systemic cancer therapies for solid tumours-a comparison of two thresholds for meaningful clinical benefit.欧洲药品管理局（EMA）批准的用于实体瘤的五年全身癌症治疗——两种有意义临床获益阈值的比较
Eur J Cancer. 2017 Sep;82:66-71. doi: 10.1016/j.ejca.2017.05.029. Epub 2017 Jul 10.
6
Reply to the letter to the editor 'Still a long way to go to achieve multidisciplinarity for the benefit of patients: commentary on the ESMO position paper' by Valentini et al.对瓦伦蒂尼等人致编辑的信《为了患者的利益实现多学科整合仍有很长的路要走：对欧洲肿瘤内科学会立场文件的评论》的回复
Ann Oncol. 2014 Sep;25(9):1865. doi: 10.1093/annonc/mdu246. Epub 2014 Jul 15.
7
Comment on ESMO Magnitude of Clinical Benefit Scale.
Ann Oncol. 2015 Dec;26(12):2504. doi: 10.1093/annonc/mdv384. Epub 2015 Sep 14.
8
The European Society for Medical Oncology 'Magnitude of Clinical Benefit Scale' field-tested in infrequent tumour entities: an extended analysis of its feasibility at the Medical University of Vienna.欧洲医学肿瘤学会“临床获益程度量表”在罕见肿瘤实体中的现场测试：维也纳医科大学对其可行性的扩展分析
ESMO Open. 2017 Jul 16;2(3):e000166. doi: 10.1136/esmoopen-2017-000166. eCollection 2017.
9
Reply to the Letter to the Editor 'Risk-adapted modulation through de-intensification of cancer treatments: an ESMO classification' by Hannoun-Levi et al.对Hannoun-Levi等人致编辑的信《通过癌症治疗降阶梯进行风险适应性调整：ESMO分类》的回复
Ann Oncol. 2022 Dec;33(12):1331-1333. doi: 10.1016/j.annonc.2022.09.154. Epub 2022 Sep 15.
10
Reply to the letter to the editor 'Utilisation of the ESMO-MCBS in practice of HTA' by Wild et al.对怀尔德等人致编辑的信《ESMO-MCBS在卫生技术评估实践中的应用》的回复
Ann Oncol. 2016 Nov;27(11):2136-2137. doi: 10.1093/annonc/mdw406. Epub 2016 Aug 29.
Zotero 插件